{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:27:03Z","timestamp":1793273223046,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2T32GM086308-11"],"award-info":[{"award-number":["2T32GM086308-11"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018578","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["1KL2TR001411"],"award-info":[{"award-number":["1KL2TR001411"]}],"id":[{"id":"10.13039\/100018578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018578","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}],"id":[{"id":"10.13039\/100018578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2T32GM086308-11"],"award-info":[{"award-number":["2T32GM086308-11"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["1KL2TR001411"],"award-info":[{"award-number":["1KL2TR001411"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The comparative effectiveness of biologic agents used as add-on therapy in the management of difficult-to-control asthma is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness of dupilumab, mepolizumab, and benralizumab among patients with difficult-to-control asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective multicenter cohort study of adult patients with difficult-to-control asthma starting treatment with dupilumab, mepolizumab, or benralizumab as documented in a multicenter electronic health record and claims-based database between October 19, 2018, and September 30, 2022. Propensity-score matching was used to minimize bias from nonrandomized treatment assignment; a prespecified \u03b1-level was set at 0.017 to account for three primary comparisons. The exposure of interest was the new initiation of dupilumab, benralizumab, or mepolizumab treatment. The primary outcome was the rate of asthma exacerbations in the 1\u2009year after initiation of biologic therapy modeled using a negative binomial approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 893,668 patients with asthma who were prescribed an inhaled corticosteroid and were \u2a7e12\u2009years old (65% female; mean age, 49\u2009yr), 3,943 started dupilumab, 1,902 started benralizumab, and 2,012 started mepolizumab, all without an alternative indication for biologic therapy. After matching, there were 1,805 patients in each group for comparisons between dupilumab and benralizumab, 1,865 for comparisons between dupilumab and mepolizumab, and 1,721 for comparisons between mepolizumab and benralizumab. For all pairwise comparisons, covariates were well balanced after matching (all standardized mean differences &amp;lt;0.1). Patients who initiated dupilumab had a significantly lower rate of asthma exacerbations (1.07 per year) compared with benralizumab (1.47 per year), with a rate ratio (RR) of 0.73 (95% confidence interval, 0.63\u20130.85), and also had a significantly lower rate of asthma exacerbations compared with mepolizumab (1.04 per year vs. 1.45 per year), with an RR of 0.72 (0.62\u20130.84). There was no statistically significant difference in the rate of asthma exacerbations between mepolizumab (1.40 per year) and benralizumab (1.41 per year), with an RR of 1.00 (0.85\u20131.17).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with difficult-to-control asthma who had newly initiated biologic therapy, dupilumab was associated with a decreased rate of asthma exacerbations in the 1\u2009year after initiation compared with mepolizumab or benralizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202306-566oc","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:05:22Z","timestamp":1705662322000},"page":"866-874","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-Matched Analysis"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-9157","authenticated-orcid":false,"given":"Christopher M.","family":"Kearney","sequence":"first","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Sangani","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Shankar","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-0316","authenticated-orcid":false,"given":"Anica C.","family":"Law","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Walkey","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Bosch","sequence":"additional","affiliation":[{"name":"The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"2026012203155493700_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"key":"2026012203155493700_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jama.2017.8372","article-title":"Diagnosis and management of asthma in adults: a review","volume":"318","author":"McCracken","year":"2017","journal-title":"JAMA"},{"key":"2026012203155493700_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","article-title":"The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA","volume":"17","author":"Suruki","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2026012203155493700_bib4","author":"Global Strategy for Asthma Management and Prevention","year":"2022"},{"key":"2026012203155493700_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12931-017-0524-y","article-title":"Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients","volume":"18","author":"Seys","year":"2017","journal-title":"Respir Res"},{"key":"2026012203155493700_bib6","doi-asserted-by":"crossref","first-page":"00576-2021","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026012203155493700_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"2026012203155493700_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma--present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026012203155493700_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012203155493700_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"2026012203155493700_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012203155493700_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203155493700_bib13","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203155493700_bib14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026012203155493700_bib15","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2026012203155493700_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203155493700_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203155493700_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203155493700_bib19","year":"2017"},{"key":"2026012203155493700_bib20","year":"2017"},{"key":"2026012203155493700_bib21","year":"2021"},{"issue":"suppl","key":"2026012203155493700_bib22","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jaci.2011.12.983","article-title":"Asthma outcomes: exacerbations","volume":"129","author":"Fuhlbrigge","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203155493700_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2026012203155493700_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2026012203155493700_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00161507","article-title":"Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited","volume":"32","author":"Keene","year":"2008","journal-title":"Eur Respir J"},{"key":"2026012203155493700_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/01621459.1961.10482090","article-title":"Multiple comparisons among means","volume":"56","author":"Dunn","year":"1961","journal-title":"J Am Stat Assoc"},{"key":"2026012203155493700_bib27","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"2026012203155493700_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203155493700_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00408-019-00310-8","article-title":"Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis","volume":"198","author":"Ramonell","year":"2020","journal-title":"Lung"},{"key":"2026012203155493700_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00408-018-0151-5","article-title":"Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis","volume":"196","author":"Iftikhar","year":"2018","journal-title":"Lung"},{"key":"2026012203155493700_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2026012203155493700_bib32","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"2026012203155493700_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","article-title":"Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses","volume":"362","author":"Minty","year":"1993","journal-title":"Nature"},{"key":"2026012203155493700_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nm734","article-title":"Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma","volume":"8","author":"Kuperman","year":"2002","journal-title":"Nat Med"},{"key":"2026012203155493700_bib35","first-page":"PA3877","article-title":"Broader impact of IL-4Ra blockade than IL-5 blockade on type 2 inflammation [abstract]","volume":"54","author":"Allinne","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012203155493700_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"2026012203155493700_bib37","doi-asserted-by":"crossref","first-page":"K12","DOI":"10.1016\/j.vaccine.2013.06.091","article-title":"A systematic review of validated methods to capture acute bronchospasm using administrative or claims data","volume":"31","author":"Sharifi","year":"2013","journal-title":"Vaccine"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/6\/866\/66011340\/annalsats_21_6_866.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/6\/866\/66011340\/annalsats_21_6_866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:17:04Z","timestamp":1769069824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/6\/866\/8382001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202306-566oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"2023-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}